WALTHAM, Mass.–(BUSINESS WIRE)–OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the
discovery, development and commercialization of new treatment options,
today announced that Christophe Couturier, Chief Financial Officer of
OvaScience, will present a corporate overview at two upcoming
Cowen and Company 37th Annual Health Care Conference
Monday, March 6, 2017
Time: 2:00 p.m. ET
Oppenheimer 27th Annual Healthcare Conference
March 21, 2017
Time: 3:55 p.m. ET
Live audio webcasts of the presentations can be accessed by visiting the
investor section of the company’s website at www.ovascience.com.
A replay of the webcasts will be archived on the OvaScience website for
30 days following the presentations.
OvaScience, Inc. (NASDAQ: OVAS) is a global fertility company dedicated
to improving treatment options for women around the world. OvaScience is
discovering, developing and commercializing new fertility treatments
because it believes women deserve more options. Each OvaScience
treatment is based on the Company’s proprietary technology platform that
leverages the breakthrough discovery of egg precursor (EggPC℠) cells –
immature egg cells found inside the protective ovarian lining.
OvaScience is developing the OvaPrime℠ treatment, which could increase a
woman’s egg reserve, and the OvaTure℠ treatment, a potential
next-generation in vitro fertilization (IVF) treatment that could help a
woman produce healthy, young, fertilizable eggs without hormone
injections. OvaScience’s AUGMENT℠ treatment, a fertility option designed
to improve IVF success rates, is available in certain IVF clinics in
select international regions. OvaScience treatments are not available in
the U.S. For more information, visit www.ovascience.com.
Media and Investor Contact: